NEA Management Company’s Aurinia Pharmaceuticals AUPH Stock Holding History

NEA Management Company’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$58.8M	Hold	3,969,834	–	–	3.34%	10
2025 Q4	$63.3M	Hold	3,969,834	–	–	3.23%	10
2025 Q3	$43.9M	Hold	3,969,834	–	–	2.41%	15
2025 Q2	$33.6M	Hold	3,969,834	–	–	2.53%	11
2025 Q1	$31.9M	Hold	3,969,834	–	–	2.46%	10
2024 Q4	$35.6M	Hold	3,969,834	–	–	2.01%	13
2024 Q3	$29.1M	Hold	3,969,834	–	–	1.59%	15
2024 Q2	$22.7M	Hold	3,969,834	–	–	1.71%	13
2024 Q1	$19.9M	Hold	3,969,834	–	–	1.23%	21
2023 Q4	$35.7M	Hold	3,969,834	–	–	2.38%	12
2023 Q3	$30.8M	Hold	3,969,834	–	–	2.38%	14
2023 Q2	$38.4M	Hold	3,969,834	–	–	2.93%	11
2023 Q1	$43.5M	Hold	3,969,834	–	–	3.01%	14
2022 Q4	$17.1M	Hold	3,969,834	–	–	0.96%	26
2022 Q3	$29.9M	Hold	3,969,834	–	–	1.49%	21
2022 Q2	$39.9M	Hold	3,969,834	–	–	2.05%	12
2022 Q1	$49.1M	Buy	3,969,834 +900,000	+29%	+$13.9M	1.42%	16
2021 Q4	$70.2M	Sell	3,069,834 -2,102,849	-41%	-$49.8M	1.42%	13
2021 Q3	$114M	Hold	5,172,683	–	–	1.36%	10
2021 Q2	$67M	Hold	5,172,683	–	–	0.87%	17
2021 Q1	$67.2M	Hold	5,172,683	–	–	1.51%	19
2020 Q4	$71.5M	Hold	5,172,683	–	–	1.89%	19
2020 Q3	$76.2M	Hold	5,172,683	–	–	3.23%	14
2020 Q2	$84.1M	Hold	5,172,683	–	–	3.38%	13
2020 Q1	$75.1M	Hold	5,172,683	–	–	3.92%	9
2019 Q4	$105M	Hold	5,172,683	–	–	4.96%	9
2019 Q3	$27.6M	Hold	5,172,683	–	–	2.29%	13
2019 Q2	$34M	Hold	5,172,683	–	–	2.38%	15
2019 Q1	$33.6M	Buy	5,172,683 +364,200	+8%	+$2.42M	1.75%	15
2018 Q4	$32.8M	Hold	4,808,483	–	–	1.3%	15
2018 Q3	$31.9M	Hold	4,808,483	–	–	1.38%	19
2018 Q2	$27.1M	Hold	4,808,483	–	–	1.27%	19
2018 Q1	$25M	Hold	4,808,483	–	–	1.11%	22
2017 Q4	$21.8M	Hold	4,808,483	–	–	0.9%	24
2017 Q3	$30.1M	Hold	4,808,483	–	–	1.06%	18
2017 Q2	$29.5M	Hold	4,808,483	–	–	1.07%	19
2017 Q1	$35.3M	Buy	4,808,483 +740,740	+18%	+$3.42M	1.23%	14
2016 Q4	$8.54M	Buy	4,067,743 +1,520,900	+60%	+$4.89M	0.34%	22
2016 Q3	$7.67M	Hold	2,546,843	–	–	0.34%	24
2016 Q2	$7.05M	Hold	2,546,843	–	–	0.37%	26
2016 Q1	$7.41M	Hold	2,546,843	–	–	0.49%	24
2015 Q4	$6.29M	Hold	2,546,843	–	–	0.4%	24
2015 Q3	$7.23M	Hold	2,546,843	–	–	0.48%	26
2015 Q2	$7.69M	Hold	2,546,843	–	–	0.4%	29
2015 Q1	$11.1M	Hold	2,546,843	–	–	0.5%	28
2014 Q4	$9.27M	Hold	2,546,843	–	–	0.45%	28
2014 Q3	$8.15M	Buy	+2,546,843	New	+$9.05M	0.41%	29

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NEA Management Company's AUPH Position: Q1 2026 in Review

NEA Management Company held its Aurinia Pharmaceuticals (AUPH) position steady in Q1 2026 at 3,969,834 shares worth $58.8M. The position accounts for 3.34% of the portfolio, ranked #10.

NEA Management Company first reported a position in AUPH in Q3 2014 and has held it in 47 quarters since. The position peaked at $114M in Q3 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

NEA Management Company held 3,969,834 shares of Aurinia Pharmaceuticals worth $58.8M as of Q1 2026.
NEA Management Company left its Aurinia Pharmaceuticals share count unchanged in Q1 2026.
Aurinia Pharmaceuticals made up 3.34% of NEA Management Company's portfolio in Q1 2026, its #10 holding.
NEA Management Company first reported a position in Aurinia Pharmaceuticals in Q3 2014 and has held it in 47 quarters since.
NEA Management Company's Aurinia Pharmaceuticals position peaked at $114M in Q3 2021.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on NEA Management Company's 13F filing for Q1 2026, filed 15 May 2026.